The Thai healthcare system faces pressure to fund high-cost new branded pharmaceuticals. Paying more may encourage innovation with positive implications for future population health, but it also means less money is available to fund other healthcare with negative implications for current population health. Recent work in the UK estimated, for the f

This project aims to support HITAP ’s capacity building strategy through individual capacity development schemes, for instance, participating in academic conferences, or providing an opportunity to work in and learn from other health technology assessment (HTA ) organizations. In addition, this project included international networking with leadi

This report summarizes the meeting on “Improving Priority Antibiotic Access in Thailand and Regional Coordinated Procurement Mechanisms,” held on 7–8 July 2025 in Bangkok, Thailand. The meeting was convened by the Health Intervention and Technology Assessment Program Foundation (HITAP), in collabora

Over the years, NICE’s guidance and methods have generated substantial interest from researchers, non-governmental organisations, health insurance funds and ministries of health and finance across the globe. NICE International was set up to respond to requests from around the world for help to impro

– The pharmaceutical industry is a significant emitter of carbon emissions, which accelerates climate change and directly affects human health and health systems. – The safety and efficacy profiles of intravenous (IV) and oral paracetamol for patients undergoing surgeries are comparable. – Swi

Mr. Nathanonl Dissakorntharavanij is currently a Research Assistant at the Health Intervention and Technology Assessment Program (HITAP). He specializes in environmental economics and public policy analysis, with a focus on utilizing data and empirical evidence to support policy decision-making at the intersection of health and climate change.Mr. N

Apirujee Punjataewakupt, PhD, earned her doctoral degree in pharmaceutical sciences from Chulalongkorn University. She has diverse experience in both the pharmaceutical industry and health-related research. She is currently serving as a research assistant at the Health Intervention and Technology Assessment Program (HITAP).Her expertise includes ph

Phornnaphat is a licensed pharmacist with a diverse academic background, holding a bachelor\'s degree in pharmacy from Silpakorn University and a master’s degree in molecular biology from Nagoya University (MEXT Scholarship). With this interdisciplinary training, she specializes in applying data and evidence to inform health policy.Her research foc

Picharee Karunayawong is a researcher and economist at the Health Intervention and Technology Assessment Program Foundation (HITAP). Her work focuses on data-driven and quantitative research aimed at improving the efficiency of national health systems and reducing the use of low-value care. She works closely with the policymakers, participating in

Abstract During COVID-19 pandemic, telemedicine was a strategy to facilitate healthcare service delivery minimizing the risk of direct exposure among people. In Thailand, the National Health Security Office has included telemedicine services under the Universal Coverage Scheme to support social d